Proceedings of the Guideline Workshop 2019: Strategies for the Optimization of Guideline Processes in Diabetes, Cardiovascular Diseases, and Kidney Diseases

被引:1
作者
Marx, Nikolaus [1 ]
Ryden, Lars [2 ]
Brosius, Frank [3 ]
Ceriello, Antonio [4 ]
Cheung, Michael [5 ]
Cosentino, Francesco [2 ]
Green, Jennifer [6 ]
Kellerer, Monika [7 ]
Koob, Susan [8 ]
Kosiborod, Mikhail [9 ,10 ,11 ]
Nedungadi, Prashant [12 ]
Rodbard, Helena W. [13 ]
Vandvik, Per Olav [14 ]
Standl, Eberhard [15 ]
Schnell, Oliver [15 ]
机构
[1] Rhein Westfal TH Aachen, Univ Hosp Aachen, Dept Internal Med 1, Aachen, Germany
[2] Karolinska Inst, Dept Med K2, Stockholm, Sweden
[3] Univ Arizona, Coll Med, Tucson, AZ 85721 USA
[4] IRCCS MultiMed, Sesto San Giovanni MI, Italy
[5] Kidney Dis Improving Global Outcomes, Brussels, Belgium
[6] Duke Univ, Duke Clin Res Inst, Med Ctr, Durham, NC USA
[7] Marienhospital Stuttgart, Stuttgart, Germany
[8] PCNA Natl Off, Madison, WI USA
[9] St Lukes Mid Amer Heart Inst, Kansas City, MO USA
[10] Univ Missouri, Kansas City, MO 64110 USA
[11] Univ New South Wales, George Inst Global Hlth, Sydney, NSW, Australia
[12] Amer Heart Assoc, Dallas, TX USA
[13] Endocrine & Metab Consultants, Rockville, MD USA
[14] Univ Oslo, Inst Hlth & Soc, Oslo, Norway
[15] Forschergruppe Diabet eV, Ingolstaedter Landstr 1, D-85764 Munich, Germany
关键词
Guidelines; Diabetes; Harmonization; Guideline workshop; CLINICAL-PRACTICE GUIDELINES; CORONARY-ARTERY-DISEASE; GRADE; RECOMMENDATIONS; NONADHERENCE; ADHERENCE; COHORT; DEATH; HEART;
D O I
10.1089/dia.2020.0086
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The Guideline Workshop 2019, held in October 2019 in Munich, Germany, had the purpose of facilitating discussion on strategies for optimization of guideline processes in diabetes among a group of representatives of renown national and international societies in the field of diabetes, cardiology, and nephrology. Results of this panel's discussions are presented in this article and comprise a variety of suggestions for improving the quality and usability of guidelines, as well as to accelerate the development and responsiveness of guidelines to newly published, relevant data from clinical trials such as cardiovascular outcome trials in diabetes mellitus. These include, but are not limited to, recommendations to optimize presentation of content in guidelines, use of the Grading of Recommendations Assessment, Development, and Evaluation approach to rating the quality of evidence to harmonize guidelines, and utilization of digital health technologies to accelerate, streamline, and optimize communication on relevant data and development of clinical guidelines and necessary updates, while reducing costs. Recognizing that achieving alignment in guideline development among various medical organizations will be a long-term process, representatives from cross-sectional medical organizations relevant to cardio/renal metabolic disease and experts in guideline methodology will work together in the future. Among other activities, it is planned to continue the activity and organize a Guideline Workshop in 2020.
引用
收藏
页码:546 / 552
页数:7
相关论文
共 49 条
[41]  
Pickup John C, 2013, J Diabetes Sci Technol, V7, P1567
[42]  
Price David, 2015, J Diabetes Sci Technol, V10, P439, DOI 10.1177/1932296815607863
[43]   Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial [J].
Sharma, Abhinav ;
Green, Jennifer B. ;
Dunning, Allison ;
Lokhnygina, Yuliya ;
Al-Khatib, Sana M. ;
Lopes, Renato D. ;
Buse, John B. ;
Lachin, John M. ;
Van de Werf, Frans ;
Armstrong, Paul W. ;
Kaufman, Keith D. ;
Standl, Eberhard ;
Chan, Juliana C. N. ;
Distiller, Larry A. ;
Scott, Russell ;
Peterson, Eric D. ;
Holman, Rury R. .
DIABETES CARE, 2017, 40 (12) :1763-1770
[44]   Impact of the Discordance Between the American College of Cardiology/American Heart Association and American Diabetes Association Recommendations on Hypertension in Patients With Diabetes Mellitus in the United States [J].
Shin, Doosup ;
Bohra, Chandrashekar ;
Kongpakpaisarn, Kullatham .
HYPERTENSION, 2018, 72 (02) :256-259
[45]  
US Food and Drug Administration, Guidance for Industry. Diabetes mellitus-evaluating cardiovscular risk in new antidiabetic therpaies to treat type 2 diabetes
[46]   Creating Clinical Practice Guidelines We Can Trust, Use, and Share A New Era Is Imminent [J].
Vandvik, Per Olav ;
Brandt, Linn ;
Alonso-Coello, Pablo ;
Treweek, Shaun ;
Akl, Elie A. ;
Kristiansen, Annette ;
Fog-Heen, Anja ;
Agoritsas, Thomas ;
Montori, Victor M. ;
Guyatt, Gordon .
CHEST, 2013, 144 (02) :381-389
[47]  
Wiviott SD, 2019, NEW ENGL J MED, V380, P347, DOI [10.1056/NEJMoa1812389, 10.1056/NEJMc1902837]
[48]   Effects of guideline adherence in primary breast cancer-A 5-year multi-center cohort study of 3976 patients [J].
Woeckel, Achim ;
Kurzeder, Christian ;
Geyer, Verena ;
Noyasphenny, Igor ;
Wolters, Regine ;
Wischnewsky, Manfred ;
Kreienberg, Rolf ;
Varga, Dominic .
BREAST, 2010, 19 (02) :120-127
[49]   SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials [J].
Zelniker, Thomas A. ;
Wiviott, Stephen D. ;
Raz, Itamar ;
Im, Kyungah ;
Goodrich, Erica L. ;
Bonaca, Marc P. ;
Mosenzon, Ofri ;
Kato, Eri T. ;
Cahn, Avivit ;
Furtado, Remo H. M. ;
Bhatt, Deepak L. ;
Leiter, Lawrence A. ;
McGuire, Darren K. ;
Wilding, John P. H. ;
Sabatine, Marc S. .
LANCET, 2019, 393 (10166) :31-39